期刊
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
卷 68, 期 4, 页码 463-471出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAI.0000000000000509
关键词
HIV; AIDS; Africa; antiretroviral therapy; drug resistance; adherence
资金
- Spanish Government [AF/NAM/BBA/701/XU/08]
- Bill and Melinda Gates Foundation [38180]
- National Institutes of Health (NIH) [1K23AI097010-01A1, L30 AI080268-02, T32 AI007438-16, K23 AIO74423-05]
- Lifespan/Tufts/Brown Center for AIDS Research [P30 AI042853]
- Harold Williams, MD Medical Student Research Fellowship, Tufts University School of Medicine
- Driscoll O'Neill Charitable Foundation
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007438, P30AI042853, K23AI074423, K23AI097010] Funding Source: NIH RePORTER
Objective: The World Health Organization (WHO) prospective surveys of acquired HIV drug resistance (HIVDR) evaluate HIVDR emerging after the first year of antiretroviral therapy (ART) and associated factors. Methods: Consecutive ART starters in 2009 were enrolled at 3 sentinel sites in Namibia. Genotyping was performed at start and after 12 months in patients with HIV viral load (VL) >1000 copies per mL. HIVDR outcomes were: HIVDR prevention (VL <= 1000 copies/mL), possible HIVDR (VL >1000 copies/mL without detectable HIVDR or loss to follow-up or ART stop), and HIVDR (VL>1000 copies/mL with detectable HIVDR). Adherence was assessed using medication possession ratio (MPR). Results: Of 394 starters, at 12 months, 80% were on first-line ART, 1% died, 4% transferred out, 1% stopped ART, <1% switched to second-line, and 15% were lost to follow-up. Among patients on first-line, 77% had VL testing, and 94% achieved VL <= 1000 copies per mL. At baseline, 7% had HIVDR. After 12 months, among patients with VL testing, 5% had HIVDR. A majority of patients failing therapy had high-level resistance to nonnucleoside reverse transcriptase inhibitors but none to protease inhibitors. All sites achieved the WHO target of >= 70% HIVDR prevention. Factors associated with not achieving HIVDR prevention were: baseline resistance to nonnucleoside reverse transcriptase inhibitors [odds ratio (OR) 3.0, P = 0.023], WHO stage 3 or 4 at baseline (OR 2.0, P = 0.012), and MPR,75% (OR 4.9, P = 0.021). Conclusions: Earlier ART initiation and removal of barriers to on-time drug pickups may help to prevent HIVDR. These data inform decisions at national and global levels on the effectiveness of first- and second-line regimens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据